Obesity Treatment Firm, EnteroMedics, Begins Commercializing Neurostimulation Device

Obese Australians will be among the first in the world to use a Minnesota company’s therapy that uses an implantable neurostimulator to achieve weight loss. EnteroMedics (NASDAQ:ETRM) announced this week that it has shipped its first commercially available MaestroRechargeable System to its distribution partner in Australia. The Maestro system deliversVBLOC (vagus nerve-blocking therapy) designed to control both hunger and the feeling of fullness in the human digestive system.

Back to news